Adaptive Biotechnologies Corporation reported $308M of revenue over the trailing twelve months, +50% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $308M (to Q2 2026). Net income: −$64M, trailing twelve months to Q2 2026. Free cash flow: −$24M, trailing twelve months to Q2 2026. Operating margin: −14%, trailing twelve months to Q2 2026.

ADPTAdaptive Biotechnologies Corporation

Healthcare

$26.49+98% 1Y

$26.49

$12.4152 weeks$29.86

ADPT as reported

Adaptive Biotechnologies Corporation reported $308M of revenue over the trailing twelve months, +50% on the year before. 10 reported series are charted on this page, each one as filed.

$308M

Revenue, trailing twelve months · to Q2 2026 · +50% against the twelve months before

Net income: −$64M
Net income · −47% year on year · trailing twelve months to Q2 2026
Free cash flow: −$24M
Free cash flow · −71% year on year · trailing twelve months to Q2 2026
Operating margin: −14%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for ADPT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$308M	+50%	Q2 2026
Net income	−$64M	−47%	Q2 2026
EPS	−$0.41	−49%	Q2 2026
Gross margin	75%	n/a	Q2 2026
Operating margin	−14%	n/a	Q2 2026
Net margin	−23%	n/a	Q2 2026
ROE	−33%	n/a	Q2 2026
ROA	−12%	n/a	Q2 2026
ROIC	−25%	n/a	Q2 2026
Free cash flow	−$24M	−71%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.